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	Abstract
The	pharmacokinetics	and	oral	bioavailability	of	two	tylosin	formulations	was	carried	out	in	broiler	chickens	according	to	
a	single	dose,	randomized,	parallel	design.	The	two	formulations	of	tylosin	(Tylosina®	and	Tylan®)	were	given	orally	at	a	
dose	level	of	25	mg/kg	b.w.	after	an	overnight	fasting	(n=15	chicken/group).	To	calculate	tylosin	bioavailability,	fifteen	more	
chickens	was	assigned	as	group	3	and	was	given	a	single	intravenous	dose	of	tylosin	(25	mg/kg	b.w.).	Serial	blood	samples	
were	collected	at	different	time	points	up	to	24	hour	post-drug	administration.	A	high	performance	liquid	chromatography	
(HPLC)	method	was	used	for	the	determination	of	tylosin	concentrations	in	chicken	plasma.	The	pharmacokinetics	analysis	of	
the	data	was	performed	using	non-compartmental	analysis	based	on	statistical	moment	theory	with	the	help	of	commercially	
available	software	(WinNonlin®,	Pharsight	Corporation,	Cary,	NC,	USA).	There	were	no	significant	differences	in	the	C
max
	
(3.05±0.63,	2.63±0.74	μg/ml),	t
max
	(2.36±0.42,	2.30±0.38	h),	t
1/2β
	(1.99±0.38,	2.67±0.60	h),	AUC
0-12h
	(6.11±0.97,	5.37±1.16	
μg.h/ml),	AUC
0-∞
	(6.38±0.94,	5.57±1.15	μg.h/ml),	MRT	(3.53±0.24,	3.67±0.32	h),	Cl
B
/F	(90.59±13.81,	169.38±54.44	ml/
min/kg)	and	Vd
z
/F	(16.85±4.74,	43.96±18.24	l/kg)	between	Tylosina®	and	Tylan®,	respectively.	The	calculated	oral	bio-
availability	(F)	for	Tylosina®	and	Tylan®	were	40.56	and	35.41%,	respectively.		Moreover,	the	relative	bioavailability	of	
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Tylosina®	was	113.9%	when	compared	to	Tylan®.	In	conclusion,	Tylosina®	is	comparable	to	Tylan®	and	both	formulations	
can	be	used	for	treatment	of	susceptible	microorganisms	in	veterinary	medicine	practice	at	a	dose	level	of	25	mg/kg	b.w.
Keywords: tylsoin,	pharmacokinetics,	bioavailability,	chicken.
IntRoduCtIon
Tylosin	is	a	macrolide	antibiotic,	registered	exclusively	for	veterinary	use	and	was	first	described	by	Stark	
et	 al.	 (1961).	Tylosin	 is	 active	against	Gram-positive	
bacteria,	anaerobic	bacteria	and	mycoplasmas	(Giguere	
2006).	It	is	indicated	primarily	for	the	treatment	of	chronic	
respiratory	 disease	 complex	 caused	by	Mycoplasma 
gallisepticum and	synoviae	 in	chickens	and	 infectious	
sinusitis	in	turkeys	(Montesissa	et	al.	1999	,	Kowalski	et	
al.	2002).	On	the	other	hand,	it	is	prescribed	extensively	
for	 the	 treatment	 of	 bovine	 and	 swine	 respiratory	
infections	 (Taha	et	 al.	 1999,	Prats	 et	 al.	 2002,	Saurit	
et	 al.	 2002).	Tylosin	 is	 considered	as	 a	bacteriostatic	
time-dependent	antibacterial	agent	that	inhibits	bacterial	
protein	synthesis	through	blocking	the	translocation	step	
(Burrows	1980,	McKellar	et	al.	2004,	Giguere	2006).	
Mycoplasmas	 are	 of	 considerable	 veterinary	
importance,	causing	infections	of	the	respiratory	and	
urogenital	 tracts,	mammary	 glands,	 joints	 and	 eyes	
of	poultry	and	livestock	species	(Hannan	et	al.	1997,	
Jordan	 et	 al.	 1998,	David	 2003,	Loria	 et	 al.	 2003).	
Tylosin	is	still	considered	as	one	of	the	most	effective	
antimicrobial	 agents	 against	 different	mycoplasmas	
species	and	has	more	activity	against	mycoplasma	than	
bacteria	(Burrows	1980,	Atef	et	al.	1991,	Kowalski	et	
al.	2002).
Several	 pharmacokinetic	 studies	 have	 been	
reported	 for	 tylosin	 in	 cows	 and	buffalo	 (Gingerich	
et	 al.	 1977,	 Saurit	 et	 al.	 2002),	 camels	 (Ziv	 et	 al.	
1995),	pigs	(Prats	et	al.	2002),	sheep	and	goats	(Atef	
et	al.	1991,	Taha	et	al.	1999)	and	dogs	(Weisel	et	al.	
1977).	Despite	the	extensive	use	of	tylosin	in	poultry	
industry,	 limited	 information	 is	 currently	 available	
about	 pharmacokinetic	 disposition	 of	 tylosin	 in	
broiler	chickens	(Kowalski	et	al.	2002).	Accordingly,	
the	 aim	 of	 the	 present	 study	was	 to	 determine	 the	
pharmacokinetics	 and	 oral	 bioavailability	 of	 two	
tylosin	formulations.	The	results	of	the	present	study	
may	contribute	to	the	further	understand	tylosin	plasma	
disposition	kinetics	in	broiler	chickens.
MAtERIAlS And MEthodS
drugs
Tylosina®	20%	liquid	solution	(NeoFarma,	Italy)	
and	Tylan®	100%	water	soluble	powder	(Elanco,	USA)	
were	 used	 for	 oral	 administration.	Tylosin	 standard	
(Tylosin	 tartate,	 90	%,	 Sigma-Aldrich,	 St	 Louis,	
Περίληψη
	Η	φαρμακοκινητική	και	βιοδιαθεσιμότητα	δύο	σκευασμάτων	τυλοσίνης	χορηγούμενων	από	το	στόμα	πραγματοποιήθηκε	
σε	 κοτόπουλα	 κρεατοπαραγωγής	 με	 την	 μέθοδο	 απλής	 δόσης,	 τυχαιοποιημένου	 και	 παράλληλου	 σχεδιασμού.	 Τα	 δύο	
σκευάσματα	της	τυλοσίνης	(Tylosina®	και	Tylan®)	χορηγήθηκαν	από	το	στόμα	σε	δόση	25	mg/kg	σ.β.	μετά	από	νηστεία	
μιας	βραδιάς	 (n=15	κοτόπουλα/ομάδα).	Για	 τον	υπολογισμό	 της	βιοδιαθεσιμότητας	 της	 τυλοσίνης,	 δεκαπέντε	 επιπλέον	
κοτόπουλα	ορίστηκαν	ως	ομάδα	3	και	τους	χορηγήθηκε	μια	απλή	ενδοφλέβια	δόση	τυλοσίνης	25	mg/kg	σ.β.	Δείγματα	αίματος	
συλλέχθηκαν	σε	διάφορους	χρόνους	μέχρι	και	24	ώρες	μετά	τη	χορήγηση	του	φαρμάκου.	Η	μέθοδος	της	υγροχρωματογραφίας	
υψηλής	 απόδοσης	 (HPLC)	 χρησιμοποιήθηκε	 για	 τον	 προσδιορισμό	 των	 συγκεντρώσεων	 της	 τυλοσίνης	 στο	 πλάσμα.	Η	
φαρμακοκινητική	 ανάλυση	 των	 δεδομένων	 πραγματοποιήθηκε	 χρησιμοποιώντας	 την	 ανάλυση	 του	 μη	 διαμερισματικού	
προτύπου	με	τη	στατιστική	θεωρεία	στιγμής	και	τη	βοήθεια	εμπορικά	διαθέσιμου	υπολογιστικού	προγράμματος	(WinNonlin®,	
Pharsight	Corporation,	Cary,	NC,	USA).	Δεν	υπήρχαν	σημαντικές	διαφορές	στην	τιμή	C
max
	(3.05±0.63,	2.63±0.74	μg/ml),	
t
max
	(2.36±0.42,	2.30±0.38	h),	t
1/2β
	(1.99±0.38,	2.67±0.60	h),	AUC
0-12h
	(6.11±0.97,	5.37±1.16	μg.h/ml),	AUC
0-∞
	(6.38±0.94,	
5.57±1.15	μg.h/ml),	MRT	(3.53±0.24,	3.67±0.32	h),	Cl
B
/F	(90.59±13.81,	169.38±54.44	ml/min/kg)	και	Vd
z
/F	(16.85±4.74,	
43.96±18.24	 l/kg)	 μεταξύ	 των	 σκευασμάτων	Tylosina®	 και	 Tylan®,	 αντίστοιχα.	Η	 υπολογισμένη	 βιοδιαθεσιμότητα	 (F)	
από	το	στόμα	ήταν		40,56	και	35,41%,	αντίστοιχα.	Επιπλέον,	η	σχετική	βιοδιαθεσιμότητα	του	Tylosina®	ήταν	113,9%	σε	
σχέση	με	το	Tylan®.	Συμπερασματικά,	το	σκεύασμα	Tylosina®	είναι	συγκρίσιμο	με	το	σκεύασμα	Tylan®	και	αμφότερα	τα	
σκευάσματα	μπορούν	να	χρησιμοποιηθούν	για	την	αντιμετώπιση	ευαίσθητων	μικροοργανισμών	στην	κτηνιατρική	πράξη	
σε	δόση	25	mg/kg	σ.β.
Λέξεις ευρετηρίασης: τυλοσίνη,	φαρμακοκινητική,	βιοδιαθεσιμότητα,	κοτόπουλο
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USA)	was	 used	 for	 intravenous	 injection.	The	drug	
was	 dissolved	 in	water	 for	 injection	 to	 give	 a	 final	
concentration	of	200	mg/ml	prior	administration.	
Experimental animals
Forty	five	broiler	chickens	(Hubbard	x	Hubbard)	
of	 35-40	days	 old,	weighing	 from	1.7	 -	 2.0kg	were	
used	in	this	study.	The	chickens	were	purchased	from	
local	 poultry	 farm.	They	were	 placed	 in	 the	 animal	
house	at	Jordan	University	of	Science	and	Technology	
(JUST).	The	animals	were	monitored	for	2	weeks	for	
any	 apparent	 clinical	 signs	 of	 disease	 before	 drug	
administration.	 The	 animal	 house	 temperature	was	
maintained	at	25	±	2°C	and	humidity	at	45–65%.	The	
chickens	had	 free	 access	 to	water	 and	 antibacterial-
free	food	(consisted	of	maize,	soybean,	and	premix)	
ad	libitum	daily.	
Experimental design  
The	chickens	were	allotted	into	3	groups.	Chickens	
of	group	1	and	2	 (n=	15/group)	were	given	a	single	
oral	dose	of	Tylosina®	and	Tylan®	at	a	dose	level	of	
25	mg/kg	b.w.	The	dose	was	chosen	according	to	the	
manufacturers’	 instruction.	Chickens	were	weighed	
prior	drug	administration	and	the	doses	were	calculated	
accordingly.	Tylosin	was	given	directly	into	the	crop	
using	a	thin	plastic	tube	attached	to	a	syringe.	Chickens	
of	 group	 3	 (n=15)	was	 given	 a	 single	 intravenous	
dose	of	 standard	 tylosin	powder	 (25	mg/kg	b.w.)	 in	
the	 right	 brachial	 vein.	Food	was	withheld	 for	 12	h	
before	drug	administration	and	was	offered	6	h	after	
drug	administration.	The	study	followed	a	randomized	
parallel	design.	All	procedures	were	approved	by	the	
animal	care	and	use	committee,	Faculty	of	Veterinary	
Medicine,	JUST.
 Sample collection
Blood	 samples	 (1-1.5	ml)	were	 collected	 from	
the	 left	brachial	vein	and	cutaneous	ulnar	veins	 into	
heparinized	tubes	at	0	(pre-treatment),	10,	20,	30,	45	
min,	and	at	1,	1.5,	2,	4,	6,	8,	10,	12	and	24	h	after	oral	
administration.	After	intravenous	administration,	blood	
samples	were	collected	at	0,	5,	15,	30	and	45	min	and	
1,	2,	4,	6,	8,	10,	12,	24	h.	The	samples	were	centrifuged	
directly	at	1000x	g	for	5	min	and	then	the	plasma	was	
harvested	and	stored	at	-20	°C	and	analyzed	within	72	
h	after	collection.
Analytical method and sample preparation
The	High	Performance	Liquid	Chromatography	
(HPLC)	method	has	 been	modified	 from	previously	
described	method	 (Abu-Basha	 et	 al.	 2007,	 Juhel-
Gaugain	et	al.	1999).	Briefly,	frozen	plasma	samples	
were	thawed	at	room	temperature	and	200	μl	plasma	
were	taken	to	Eppendorf	tube	and	precipitated	with	200	
μl	perchloric	acid	(8%)	(Sigma-Aldrich,	St	Louis,	MO,	
USA).	Each	sample	was	shaken	with	vortex	mixer	for	
30	seconds	and	then	centrifuged	for	5	min	at	1500x	g.	
The	clear	supernatant	was	transferred	into	glass	insert,	
fitted	into	auto-sampler	vial	and	100	μl	was	injected	
into	the	HPLC	system	(Shimadzu, Japan).		
The	 chromatographic	 separation	was	 performed	
using	a	purospher	Star	RP-18e	(5	μm,	125	mm	×	4.6	
mm)	 column	 (Merck,	Germany)	with	 an	 isocratic	
mobile	 phase	 of	 acetonitril:	water	 (30:	 70)	 (HPLC-
grade	Scharlau	Chemie	S.A.,	Barcelona,	Spain)	 and	
0.5%	of	triflouroacetic	acid	(Sigma-Aldrich,	St	Louis,	
MO,	USA)	was	added	to	the	mobile	phase.	The	mobile	
phase	was	filtered	through	a	0.45	μm	membrane	filter	
(Millipore,	Billerica,	MA,	USA)	 and	degassed.	The	
mobile	phase	was	eluted	at	flow	rate	of	1.5	ml/min	and	
detected	at	UV	wavelength	of	287	nm.	
Calibration curve and validation procedure
A	 standard	 calibration	 curve	was	 prepared	 by	
adding	20	μl	of	tylosin	(1	mg/ml)	to	980	μl	antibacterial-
free	 chicken	 plasma.	This	was	 further	 diluted	 into	
antibacterial-free	chicken	plasma	to	produce	standard	
of	0.025,	0.05,	0.1,	1,	5,	10,	25	and	50	μg/ml.	Standard	
solutions	were	 extracted	 and	 analyzed	 in	 the	 same	
manner	as	unknown	samples.	Calibration	curves	were	
obtained	by	calculating	the	area	of	tylosin	and	plotting	
them	against	the	corresponding	concentration	of	tylosin	
spiked	in	chicken	plasma	by	integration	peak	program	
(Class-vp	Shimadzu, Japan).
The	HPLC	method	was	 validated	 by	 assessing	
linearity,	 precision,	 recovery	 and	 sensitivity.	 Two	
standard	 calibration	 curves	with	 8	 concentrations	
(0.025,	 0.05,	 0.1,	 1,	 5,	 10,	 25	 and	50	μg/ml)	 and	6	
sets	of	quality	control	samples	(0.25,	2.5	and	7.5	μg/
ml)	were	prepared	and	analyzed	three	times	daily	for	
3	consecutive	days.	The	calibration	curves	were	linear	
over	 the	 range	 of	 0.025-50	μg/ml	 (r2>0.9996).	The	
calculated	 limit	of	detection	 (LOD)	and	 the	 limit	of	
quantification	(LOQ)	were	0.025	and	0.05	μg/ml	based	
on	a	signal-to-noise	ratio	of	3:1	and	6:1,	respectively.	
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The	mean	analytical	recovery	percentage	of	tylosin	in	
plasma	was	ranged	from	92.6	to	98.4%.	The	inter-	and	
intra-day	assay	coefficients	of	variation	ranged	from	
1.54	to	6.75%	at	concentrations	of	0.25,	2.5	and	7.5	μg/
ml.	The	accuracy	ranged	from	97.8-	100.2%.	
Pharmacokinetic and statistical analysis 
The	 pharmacokinetic	 analysis	 of	 the	 data	was	
performed	 using	 non-compartmental	method	 based	
on	 statistical	moment	 theory	 (SMT)	 according	 to	
previously	 described	method	 (Gibaldi	 and	 Perrier	
1982),	 	 using	 the	 commercially	 available	 	 software	
(Win	Nonlin®,	Pharsight	Corporation,	Cary,	NC,	USA).	
The	 calculated	 parameters	were:	 area	 under	 plasma	
concentration-time	 curve	 (AUC)	 and	 the	 area	 under	
the	moment	 curve	 (AUMC)	 using	 linear	 trapezoid	
method;	mean	 residence	 time	 (MRT),	where	MRT=	
AUMC/AUC;	volume	of	distribution	(Vd
z
/F),	where	
Vd
z
/F	=	dose/AUC.β;	elimination	rate	constant	 (k
el
),	
which	is	the	slope	of	the	terminal	log-linear	portion	of	
the	plasma	concentration-time	profile,	determined	by	
least	squares	regression;	AUC	and	AUMC	extrapolated	
to	 infinity,	 by	 adding	 the	 ratio	Clast/k
el
;	 elimination	
half-life	 (t
1/2β
),	where	 t
1/2β
	 =	 0.639/	 k
el
	 ;	 total	 body	
clearance	 (Cl
B
/F),	 where	 Cl
B
/F	 =	 dose/AUC;	 The	
maximum	concentration	(C
max
)	and	the	corresponding	
peak	time	(t
max
)	were	determined	by	the	inspection	of	
the	individual	drug	plasma	concentration-time	profiles.	
Relative	bioavailability	was	calculated	as	(AUC
Tylosina
®	
/AUC
Tylan
®)	x	100%.	The	absolute	bioavailability	(F)	
was	calculated	as	(AUC
non-IV
	/AUC
IV
)	x	100%.
Differences	 between	 the	 pharmacokinetic	
parameters	 of	 the	 two	 tested	 formulations	 were	
evaluated	by	one-way	analysis	of	variance	(ANOVA)	
using	 the	 commercially	 available	 software	 package	
(SPSS	 Inc.,	 version	 10.0,	Chicago,	 IL,	USA).	Data	
were	expressed	as	mean	±	SE.	The	differences	were	
considered	significant	when	P<0.05.	
RESultS
All	 chickens	 used	 in	 the	 present	 study	 were	
clinically	healthy	throughout	the	experimental	period	
and	 both	 products	were	well	 tolerated.	Unexpected	
incidents	that	could	have	influenced	the	outcome	of	the	
study	did	not	occur.	The	mean	plasma	concentration	
was	35.45±1.93	μg/ml	at	5	min	following	intravenous	
administration	of	tylosin	(25	mg/kg	b.w.).	The	plasma	
concentration	was	 sharply	 decreased	 to	 reach	 the	
detection	limit	(0.05±0.01	μg/ml)	at	12	h	post-injection.	
Figure 1. Semilogarthimic	plot,	showing	the	mean	plasma	concentrations–time	profile	of	tylosin	in	
chickens	after	a	single	intravenous	and	oral	administration	at	a	dose	level	of	25	mg/kg	b.w.	Values	are	
mean	±	SE	(n=15/group).
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The	mean	concentrations–time	profile	for	tylosin	after	
intravenous	administration	is	shown	in	Figure	1.		
The	 concentrations	 of	 tylosin	 in	 chicken	plasma	
were	 determined	 up	 to	 12	 h	 and	 were	 below	 the	
detectable	 limit	 in	 all	 chickens	 24	 h	 post	 single	
oral	 administration	 for	 both	 formulations.	 Both	
formulations	were	slowly	absorbed	after	oral	dosing	
with	a	peak	plasma	concentration	(C
max
)	of	3.05±0.63	
and	2.63±0.74	μg/ml,	achieved	at	(t
max
)	2.36±0.42	and	
2.30±0.38	h,	 respectively	 for	Tylosina®	 and	Tylan®.	
The	mean	concentration–time	profile	for	tylosin	oral	
products	is	shown	in	Figure	1.
The	 oral	 bioavailability	 (F)	 for	 Tylosina®	 and	
Tylan®	 were	 40.56	 and	 35.41%,	 respectively	 and	
the	 relative	 bioavailability	was	113.9	%	 (Tylosina®/
Tylan®).	 The	 pharmacokinetics	 parameters	 after	
intravenous	 and	 oral	 administrations	 of	 the	 two	
formulations	are	shown	in	Table	1.		
dISCuSSIon
Tylosin	is	an	organic	base	with	high	lipid	solubility	
that	 achieves	 good	 tissue	 and	 barrier	 penetration,	
readily	 entering	 the	 peripheral	 compartment	 and	
allowing	the	drug	to	accumulate	at	therapeutic	levels	at	
the	targeted	site	of	infection	(Atef	et	al.	1991,	Giguere	
2006).	Tylosin	is	widely	distributed	in	the	body,	which	
attains	 higher	 concentration	 at	 the	 tissue	 compared	
to	 that	at	 the	plasma	and	has	 low	binding	 to	plasma	
proteins	(Burrows	1980,	Taha	et	al.	1999,	Brennan	et	
al.	2001).	Tylosin	is	concentrated	in	tissues	including	
table 1. Comparison	of	the	mean	plasma	pharmacokinetic	parameters	obtained	for	tylosin	in	chickens	after	a	single	intravenous	and	
oral	administration	at	a	dose	level	of	25	mg/kg	b.w.	Values	are	mean	±	SE	(n=15/	group).
C
max
, maximum plasma concentration; t
max
, time to peak concentration; t
1/2β
, elimination half-life; AUC 
0-12h
, area under 
plasma concentration-time curve from zero to 12 h post drug administration; AUC
 0-∞
, area under plasma concentration-
time curve from zero to infinity; MRT, mean residence time; F, systemic bioavailability; Cl
B
/F, total body clearance/F; 
Vd
z
/F, volume of distribution/F.
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 08/10/2019 04:50:47 |
J	HELLENIC	VET	MED	SOC	2012,	63(2)
ΠΕΚΕ	2012,	63(2)
2.30±0.38	h	,	respectively.	The	observed	C
max	
values	
were	higher	than	those	reported	in	chickens	at	a	dose	
level	 of	 10	mg/kg	 b.w.	 (1.2±0.2	 μg/ml)	 (Kowalski	
et	 al.,	 2002).	 The	 difference	 in	C
max
	 (2.2-2.5	 x)	 is	
expected	since	 the	administered	dosage	 in	our	study	
is	2.5	x	higher.	On	the	other	hand,	the	reported	t
max	
in	
this	 experiment	was	 2.36±0.42	 and	2.30±0.38	h	 for	
Tylosina®	and	Tylan®,	respectively.	These	values	were	
longer	than	those	reported	in	broiler	chickens	(1.5±0.3	
h)	 (Kowalski	 et al.	 2002).	 The	 oral	 bioavailability	
(F)	 for	 tylosin	 represented	 by	Tylosina®	 (40.56%)	
and	Tylan®	(35.41	%)	was	slightly	higher	than	those	
reported	 in	broiler	chickens	 (30	%)	 (Kowalski	et	al.	
2002).	The	differences	in	the	AUC	may	be	attributed	
to	the	differences	in	the	achieved	bioavailability.	
On	the	other	hand,	the	average	means	of	AUC
0–12
,	
AUC
0-∞
,	 C
max
	 for	 The	 two	 oral	 formulations	were	
not	significantly	different,	indicating	that	the	plasma	
profiles	 produced	 by	 Tylosina®	 are	 comparable	
to	 those	 produced	 by	 Tylan®.	 Moreover,	 no	
significant	 differences	were	 found	 among	 all	 tested	
pharmacokinetic	 parameters	 including;	 elimination	
half-life	(t
1/2β
),	mean	residence	time	(MRT),	total	body	
clearance	(Cl
B
/F)	and	volume	of	distribution	(Vd
z
/F).
Tylosin	is	a	macrolide	antibiotic	with	a	minimum	
inhibitory	 concentration	 (MIC)	values	 ranging	 from	
0.01	 to	 0.5	 μg/ml	 for	 various	 susceptible	 bacterial	
and	mycoplasmal	 pathogens	 (Jordan	 and	Horrocks	
1996,	Hannan	et	al.	1997,	Jordan	et	al.	1998,	Salmon	
and	Watts	2000).	Tylosin	(Tylosina®	and	Tylan®)	was	
detected	 in	 chicken	plasma	 at	 concentrations	 higher	
than	the	MIC	for	most	susceptible	microorganisms	and	
Mycoplasma	 for	12	h	 following	oral	administration.	
Therefore,	 oral	 tylosin	 administration	 at	 a	 dose	 of	
25	mg/kg	 b.w.	 seems	 to	 be	 a	 suitable	 therapeutic	
dose	in	broiler	chickens.	However,	repeated	doses	are	
necessary	 to	maintain	 tylosin	 plasma	 concentrations	
above	the	MIC	for	most	susceptible	microorganisms.
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lungs	at	levels	between	3	to	5	times	greater	than	those	
detected	 in	 plasma	 (Kowalski	 	 et	 al.	 2002,	Giguere	
2006).	Despite	the	extensive	use	of	tylosin	in	poultry	
industry,	 limited	 information	 is	 currently	 available	
about	the	mathematical	disposition	of	tylosin	in	broiler	
chicken.	Lack	of	 data	 about	 the	 pharmacokinetic	 of	
tylosin	in	chickens	and	other	avian	species	obligate	the	
authors	to	refer	to	other	species	such	as	sheep,	goat	and	
pigs	for	pharmacokinetics	comparison.				
After	 a	 single	 intravenous	 administration	 of	
tylosin	(25	mg/kg	b.w.),	the	elimination	half-life	(t
1/2β
)	
expresses	the	overall	rate	of	drug	elimination	and	can	
be	used	to	predict	drug	accumulation	in	the	body.	The	
mean	value	of	t
1/2β
	(2.06	±	0.30	h)	was	longer	than	those	
reported	in	broiler	chickens	(0.52	±	0.02	h)	(Kowalski	
et	al.	2002).	This	dissimilarity	may	be	attributable	to	
differences	in	the	administered	dose	(10	versus	25	mg/
kg	b.w.).	However,	this	value	was	shorter	than	those	
reported	in	sheep	and	goat	(4.75	±	0.71	and	4.24	±	0.32	
h,	respectively)	(Taha	et	al.	1999)	and	in	pigs	(4.52	h)	
(Prats	et	al.	2002).
The	 clearance	 obtained	 in	 the	 present	 study	
(28.29±2.86	ml/min/kg)	was	higher	than	those	reported	
in	 chickens	 (5.30±0.59	ml/min/kg)	 (Kowalski	 et	 al.	
2002)	and	in	sheep	and	goat	(6.89±0.94	and	8.66±1.37	
ml/min/kg,	 respectively)	 (Taha	et	 al.	1999)	and	was	
similar	to	those	reported	in	pigs	(26.8	ml/min/kg)	(Prats	
et	al.	2002).	On	the	other	hand,	the	apparent	volume	of	
distribution	(V
dz
)	provides	an	estimate	of	the	extent	of	
drug	distribution	in	the	body	in	which	drugs	with	V
dz
>	
1	l/kg	imply	a	wide	distribution	(Riviere	2009).	The	
V
dz
	value	of	4.87±0.58	 l/kg	 indicates	extensive	drug	
distribution	in	the	chickens’	body.	This	value	is	higher	
than	 those	 previously	 reported	 for	 broiler	 chicken	
(0.69±0.03	l/kg)	(Kowalski	et	al.	2002).	However,	our	
data	was	close	to	those	reported	in	sheep	and	goat	(3.12	
±	0.34	and	2.74	±	0.56	l/kg,	respectively)	(Taha	et	al.	
1999)	and	in	pigs	(1.4	l/kg)	(Prats	et	al.	2002).
Following	 oral	 administration	 of	Tylosina®	 and	
Tylan®,	both	formulations	were	slowly	absorbed	with	
a	maximum	plasma	concentrations	(C
max
)	of	3.05±0.63	
and	2.63±0.74	μg/ml	achieved	at	t
max
	of	2.36±0.42	and	
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